Month: July 2021

VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; ARREF: OTC) (“Amerigo” or the “Company”) is pleased to announce that Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile has received its first annual Renewable Energy Certificate (“REC”), issued by the International REC Standard. The REC is an Energy Attribute Certificate (“EAC”) under which MVC can reliably claim that the 308,653 MWh it consumed during the period January 1, to December 31, 2020, representing 100% of MVC’s electricity consumption, came from renewable sources. On January 1, 2020, MVC entered into a long-term power supply agreement that runs to December 31, 2037. Under this contract, all the electricity used at MVC is being supplied from renewable sources. “We are...

TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom. Psyence is developing market leading clinical trials in the field of palliative care and has partnered with Clerkenwell, which will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing. European Director Xan...

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Ladenburg Thalmann conference coordinator. A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following...

VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE | OTC:SIZYF | FRANKFURT:3EZ) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) of 24,285,715 units of the Company (the “Units”) at a price of $0.35 per Unit for gross proceeds of $8,500,000.25. Each Unit consists of one (1) common share of the Company (a “Common Share”) and one-half of one transferable Common Share purchase warrant (with two half warrants being a “Warrant”). Each Warrant entitles the holder thereof to purchase one (1) additional Common Share for a period of two (2) years from closing at a price of $0.70 per Common Share. In the event that the Common Shares have a closing price on the Canadian Securities Exchange...

Massive sulphides intersected in early drilling and core samples submitted for assayFigure 1Location of Phase 1 drill holes at Dundonald South. Red circles indicate the holes drilled to date that intersected massive and semi-massive nickel sulphides. The coloured lines represent the individual mineralized zones (A-H) that make-up the Dundonald South Deposit.Figure 2Drill hole DS-21-006 intersected BHEM target.Figure 3Massive and semi-massive sulphide mineralization from drill hole DS-21-006.Figure 4Drill hole DS-21-005 intersected BHEM target.Figure 5Two distinct massive sulphide intercepts in drill hole DS-21-005.Dundonald South Resource Extension: Phase 1 drilling to expand the current Mineral Resources has intersected massive sulfides east of the...

Conformis Settles Wright Medical Litigation Related to Patient-Specific Instruments for Use with Shoulder Implants BILLERICA, Mass., July 07, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement with Stryker Corporation (“Stryker”) resolving patent litigation involving Wright Medical Technology, Inc. and Tornier, Inc. (together, “Wright Medical”). Stryker acquired Wright Medical in November 2020.   “We are pleased to have resolved all of the ongoing patent litigation related to the Wright Medical dispute,” said Mark Augusti, President and Chief Executive Officer. “The settlement once again highlights the strength and value of our intellectual property, as well as our steadfast commitment to protecting and enforcing it.” Under the terms of the settlement, Stryker will make a...

MSP-1014, a next generation psychedelic medicine showed superior 5-HT2A receptor efficacy and safety compared to psilocybin TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that its first lead clinical candidate, MSP-1014, a differentiated next-generation psilocybin drug candidate from its Family 1 of novel, patent-pending psychedelic compounds, has further demonstrated superior efficacy and an improved safety profile in head-to-head pre-clinical comparisons to psilocybin. “There is a growing body of supporting evidence that...

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1×1 meetings at the following upcoming conference: Ladenburg Thalmann 2021 Virtual Healthcare Conference (Virtual)Presentation Date:                July 13, 2021Presentation Time:                11:00 am ETWebcast Link:                        https://wsw.com/webcast/ladenburg7/wint/2453238 A replay of the presentation will be available on the Investor Page of the company’s website (www.windtreetx.com). About Windtree TherapeuticsWindtree Therapeutics, Inc. is...

NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona’s investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The data showed that investigator assessment of wound healing of 50% or greater from baseline was present in 69% of treated wounds (n=18/26) at 3 years, 93% (n=14/15) at 4 years, 80% (n=12/15) at 5 years, and 80% (n=4/5) at 6 years. The results were reported in a poster, titled “Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa Following EB-101 Treatment of Large, Chronic Wounds,” at the Society for Pediatric Dermatology (SPD) 46th Annual...